Human TLR4 (Toll-Like Receptor 4) CLIA Kit

Human TLR4 (Toll-Like Receptor 4) CLIA Kit

Catalog Number:
CK01012928STJ
Mfr. No.:
STJC0000854
Price:
$415
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • This TLR4 CLIA Kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes.

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Toll-Like Receptor 4; Htoll; Cd Antigen Cd284
          Database Links
          About Target
          Tissue Specificity: Highly expressed in placenta, spleen and peripheral blood leukocytes. Detected in monocytes, macrophages, dendritic cells and several types of T-cells.

          Function: Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific. Both M.tuberculosis HSP70 (dnaK) and HSP65 (groEL-2) act via this protein to stimulate NF-kappa-B expression. In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-). Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via TLR2, but also partially via this receptor.
      • Properties
        • Regulatory Status
          RUO
          Reactivity
          human

          * For research use only

      • Applications
        • Application
          CLIA

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.